Insects; Venom Patents (Class 530/858)
  • Patent number: 9029080
    Abstract: The present invention relates to polypeptides, preferably from Drosophila melanogaster (DmShaI) as target for insecticides.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: May 12, 2015
    Assignee: BASF SE
    Inventors: Paul Bernasconi, John Dorsch, Lynn Stam, Scott Zitko, Nancy B. Rankl, Mike Griswold, Franz-Josef Braun, Gang Lu, Robert D. Kirkton, Barbara Wedel, Joachim Dickhaut, Angela Hofhine, Jennifer Zink, Fae Malone, Daniel Houtz, Steffen Groβ, Ramani Kandasamy, Damian O' Brecht London, Thomas M. Gurganus
  • Patent number: 9023142
    Abstract: A polypeptide solution of the present invention is a polypeptide solution in which a polypeptide derived from natural spider silk proteins is dissolved in a solvent. The solvent contains at least one selected from the following (i)-(iii): (i) DMSO; (ii) DMSO with an inorganic salt; and (iii) DMF with an inorganic salt. Further, in the present invention, an artificial polypeptide fiber is obtained by: using the polypeptide solution as a dope solution; and extruding the dope solution from a spinneret into a desolvation bath so as to eliminate the solvent from the dope solution and form a fiber to produce an undrawn yarn. Moreover, in the present invention, a polypeptide is purified by subjecting the polypeptide solution to heat treatment and thereafter removing an undissolved substance therefrom.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: May 5, 2015
    Assignee: Spiber Inc.
    Inventors: Junichi Sugahara, Kazuhide Sekiyama, Ryota Sato, Kaori Sekiyama, Mizuki Ishikawa, Shinya Murata, Kazuko Otomo
  • Patent number: 8986703
    Abstract: Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from: the polypeptide sequences of SEQ ID 1-44 or sub-sequences from these sequences, the sub-sequences having 7 amino acids or more; or from polypeptide sequences having 85% homology or more with one or more of the above sequences and contained in one or more of the following databases: GenBank, Protein Data Bank (PDB), SwissProt, Protein Information Resource (PIR), Protein Research Foundation (PRF), or CDS translations of these.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: March 24, 2015
    Assignee: PepTcell, Ltd.
    Inventors: Gregory Alan Stoloff, Wilson Romero Caparros-Wanderley
  • Patent number: 8979992
    Abstract: A polypeptide solution of the present invention is a polypeptide solution in which a polypeptide derived from natural spider silk proteins is dissolved in a solvent. The solvent contains at least one selected from the following (i)-(iii): (i) DMSO; (ii) DMSO with an inorganic salt; and (iii) DMF with an inorganic salt. Further, in the present invention, an artificial polypeptide fiber is obtained by: using the polypeptide solution as a dope solution; and extruding the dope solution from a spinneret into a desolvation bath so as to eliminate the solvent from the dope solution and form a fiber to produce an undrawn yarn. Moreover, in the present invention, a polypeptide is purified by subjecting the polypeptide solution to heat treatment and thereafter removing an undissolved substance therefrom.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: March 17, 2015
    Assignee: Spiber Inc.
    Inventors: Junichi Sugahara, Kazuhide Sekiyama, Ryota Sato, Kaori Sekiyama, Mizuki Ishikawa, Shinya Murata, Kazuko Otomo
  • Patent number: 8883152
    Abstract: A method of constructing a VHH library from an immunized camelid, using whole venom or an extract thereof. There is also provided VHH antibody fragments isolated from a library produced in hyperimmunized llama. These VHH antibody fragments were sequenced, and specifically bind ?-cobratoxin.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: November 11, 2014
    Assignee: University of Guelph
    Inventors: J. Christopher Hall, Gabrielle Richard, Michael D. McLean
  • Patent number: 8440234
    Abstract: Bee venom may be administered in a standardized formulation with or without relatively small amounts of anesthetic. In particular, the results of the combination of venom and anesthetic dramatically decreased pain and discomfort for patients undergoing apitherapy.
    Type: Grant
    Filed: May 13, 2008
    Date of Patent: May 14, 2013
    Inventor: Christopher M. Kim
  • Patent number: 8399026
    Abstract: The presently described subject matter relates to isolated spider venom peptides, which are used as potent and selective ion channel blockers, and to a composition and methods for treatment of pain.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: March 19, 2013
    Assignee: Alomone Preclinical Ltd.
    Inventors: Alon Meir, Ronit Simcha Cherki, Ela Kolb, Yael Langut, Nissim Bajayo
  • Patent number: 8383162
    Abstract: Methods and compositions for blocking calcium channels with a spider toxin from Phoneutria nigriventer are provided. For easy identification the toxin will be sometimes generally referred to as Ph?-1B herein. The toxin comprises a 55-amino acid sequence having a molecular weight of approximately 6,017. This Ph?-1B spider toxin was found to block calcium channels within the nervous system. The synthetic gene responsible for producing this toxin has been designed and cloned. This gene and/or its derivative provide a mechanism by which the toxin can be produced using recombinant DNA expression technologies. The present invention further relates to methods of treating neurological diseases and pain by applying the isolated and identified toxins. The toxin Ph?-1B may provide beneficial effects on pain and certain neurological conditions including seizures, ischemic- hypoxic, CNS damage, and neurodegenerative disorders. It was also found that the toxins are effective as tags in probing calcium channels.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: February 26, 2013
    Assignee: Universidade Federal de Minas Gerais
    Inventors: Marcus Vinícius Gómez, Marco Antônio Máximo Prado, Vânia Ferreira Prado
  • Patent number: 8357658
    Abstract: The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, apamine is used in an amount of between 1 and 10 micrograms inclusive, for the manufacture of a unit dose for subcutaneous injection, every one to six weeks, of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. The invention finds use in particular in the field of pharmacy.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: January 22, 2013
    Assignee: Assistance Publique—Hopitaux de Paris
    Inventors: Andréas Hartmann, Anne-Marie Bonnet, Michael Schüpbach
  • Patent number: 8293868
    Abstract: A family of insecticidal polypeptides expressed in the venom gland of spiders of the genera Atrax and Hadronyche have been described. Also included are polynucleotides and expression vectors encoding the polypeptides and insect viruses and cells expressing the polypeptides. Transgenic plants and insects expressing the insecticidal polypeptides are also described. The insecticidal polypeptides may be employed in methods and compositions for treating insects, insect larvae, and plants.
    Type: Grant
    Filed: January 17, 2011
    Date of Patent: October 23, 2012
    Inventors: Glenn F. King, Brianna Sollod McFarland, Graham Nicholson, Simon Gunning
  • Patent number: 8232249
    Abstract: The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, bee's venom is used in an amount of between 33 and 330 micrograms inclusive, for the manufacture of a unit dose for subcutaneous injection, every one to six weeks, of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. The invention finds use in particular in the field of pharmacy.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: July 31, 2012
    Assignee: Assistance Publique Hopitaux de Paris
    Inventors: Andréas Hartmann, Anne-Marie Bonnet, Michael Schüpbach
  • Patent number: 8076454
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: December 13, 2011
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Mohan Basavaraju Kumar
  • Patent number: 7812131
    Abstract: The subject invention provides exciting new sources for surprising, new types of toxin complex (“TC”) proteins. The subject invention includes these new classes and types of TC proteins. The subject invention also includes polynucleotides that encode the subject proteins. The subject invention further provides vectors and cells comprising these polynucleotides. The subject invention also provides novel methods of controlling insects. The subject invention relates in part to the surprising discovery that new types of TC proteins can be obtained from a widely diverse phylogenetic spectrum of organisms including, most notably and surprisingly, eukaryotic fungus.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: October 12, 2010
    Assignee: Doe AgroSciences LLC
    Inventors: Ignacio Mario Larrinua, Aaron Todd Woosley, Thomas Meade, Donald Joseph Merlo, Timothy Denver Hey, Stephanie Love Burton
  • Patent number: 7419793
    Abstract: The present invention relates to tick octopamine receptor nucleic acid molecules; to tick octopamine receptor proteins encoded by such nucleic acid molecules; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes inhibitory compounds, particularly those that specifically inhibit tick octopamine receptor activity, as well as the use of such compounds to treat animals.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: September 2, 2008
    Assignee: Heska Corporation
    Inventor: Kevin S. Brandt
  • Patent number: 7354993
    Abstract: The invention relates to isolated insecticidal polypeptides expressed in the venom gland of spiders of the genera Atrax and Hadronyche have been described. Methods of treating insects, insect larvae, and plants with the insecticidal polypeptides are also described.
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: April 8, 2008
    Inventors: Glenn F. King, Brianna Sollod McFarland, Graham Michael Nicholson, Simon Joseph Gunning
  • Patent number: 7259145
    Abstract: The present invention discloses a peptide of SEQ ID NO:1 and its variants that blocks stretch-activated ion channels. All amino acids in this peptide are D-amino acids. The peptide, designated as D-GsMTx4, is an enantiomer of a peptide GsMTX-4 present in the venom of the spider Grammostola spatulata. The present invention also discloses a method for inhibition of stretch activated ion channels in a cell. This peptide can be used for the treatment of cardiac arrhythmias and other pathologies that involve alterations in mechanical stress.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: August 21, 2007
    Assignee: The Research Foundation of State University of New York
    Inventors: Frederick Sachs, Thomas Suchyna, Phillip Gottlieb
  • Patent number: 7259254
    Abstract: The invention relates to mutant nuclear hormone receptors that encode mutant nuclear hormone receptors, in which particular amino acid residues are substituted with respect to wild type, so as to be able to detect ligand binding to the mutant receptor by either a change in a physical property of the mutant receptor and/or an transcriptional induction of a nuclear hormone receptor construct. The invention also relates to a nuclear hormone receptor response element denoted by the formula YDRXZ comprising a direct repeat (DR) comprising two half sites separated by X nucleic acid bases; wherein Z indicates the presence of at least one DR oriented in either a forward or reverse orientation; wherein Y equals 1 to 8 forward and/or reverse direct repeats; and X equals 1 to about 12.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: August 21, 2007
    Assignee: University of Kentucky Research Foundation
    Inventors: Grace Jones, Davy Jones
  • Patent number: 7244837
    Abstract: The present invention is directed to a lepidopteran octopamine/tyramine transporter. Nucleic acids encoding the transporter, and vectors and host cells comprising the nucleic acids are provided. The invention further provides a recombinant octopamine/tyramine transporter, kits and compositions comprising the transporter, and methods of identifying agents that mediate the activity of the transporter.
    Type: Grant
    Filed: January 12, 2004
    Date of Patent: July 17, 2007
    Assignees: The University of Western Ontario, Her Majesty the Queen in right of Canada as represented by the Minister, the Dept of Agriculture + Agrifood Canada
    Inventors: Tabita Malutan, Cameron Donly, Stanley Caveney
  • Patent number: 7211652
    Abstract: Compositions and methods for preventing hematophagous infestation of cattle are provided, directed at isolated proteins that disrupt platelet aggregation. Also provided are nucleotide sequences encoding the proteins. The exemplary haematollogen protein was isolated from the salivary glands of Haematobia irritans. The compositions are useful as veterinary vaccines in prevention of blood-feeding in cattle by the infesting horn fly and are also useful in treatment of thrombosis.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: May 1, 2007
    Assignee: Auburn University
    Inventors: Mary S. Cupp, Dunhua Zhang, Eddie W. Cupp
  • Patent number: 7211408
    Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: May 1, 2007
    Assignee: Merck Patent GmbH
    Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
  • Patent number: 7166693
    Abstract: The present invention is directed to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal. The present invention includes a saliva protein collection apparatus capable of collecting ectoparasite saliva proteins substantially free of contaminating material. The present invention also relates to ectoparasite saliva proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to obtain such proteins and to use such proteins to identify animals susceptible to or having allergic dermatitis. The present invention also includes therapeutic compositions comprising such proteins and their use to treat animals susceptible to or having allergic dermatitis.
    Type: Grant
    Filed: October 14, 2002
    Date of Patent: January 23, 2007
    Assignee: Heska Corporation
    Inventors: Glenn R. Frank, Shirley W. Hunter, Lynda Wallenfels
  • Patent number: 7064184
    Abstract: The methods and compositions of the present invention find use in impacting microbial pathogens and in enhancing disease resistance to pathogens, particularly by plants. The compositions of the invention include polypeptides that possess antimicrobial properties, particularly fungicidal properties, and the encoding nucleic acid molecules. The polypeptides of the invention are isolated from the hemolymph and fat bodies of insect larvae induced by injection of plant pathogenic fungi. Further provided are plant cells, plants, and seed thereof, transformed with the nucleic acid molecules of the invention so as to confer disease resistance on the plant.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: June 20, 2006
    Assignees: Pioneer Hi-Bred International, Inc., E. I. duPont de Nemours and Company
    Inventors: Daniel J. Altier, Rafael Herrmann, Albert L. Lu, Billy F. McCutchen, James K. Presnail, Janine L. Weaver, James F.H. Wong
  • Patent number: 7041808
    Abstract: It is intended to provide thermotolerant and antimicrobial proteins having a broad antibacterial spectrum and being useful in the agricultural, medical and industrial field; and plants resistant to pathogenic microorganisms. Namely, DNAs comprising the base sequences represented by SEQ ID NOS: 1 to 5 respectively; antimicrobial proteins encoded by these DNAs; and fungicides, antibacterial agents and antibacterial/antifungal agents for industrial use comprising the antimicrobial proteins as the active ingredient.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: May 9, 2006
    Assignee: National Institute of Agrobiological Sciences
    Inventors: Tetsuya Tomie, Michito Tagawa, Minoru Yamakawa, Jun Ishibashi
  • Patent number: 6806358
    Abstract: A potent peptide inhibitor (SuperSog) of TGF-&bgr; family growth factor signalling, peptide variants thereof and nucleotide coding sequences therefor are provided by the invention. The Super-Sog peptide comprises a fragment of the Drosophilia short gastrulation (Sog) gene which includes the CR-1 cysteine-rich repeat of Sog. Methods and compositions for use of Super-Sog in therapeutic and diagnostic applications are also provided.
    Type: Grant
    Filed: December 16, 1998
    Date of Patent: October 19, 2004
    Assignee: University of California San Diego
    Inventors: Ethan Bier, Kweon Yu
  • Patent number: 6800290
    Abstract: Variants of allergens of Dermatophagoides pteronyssinus species with reduced allergenic activity.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: October 5, 2004
    Assignee: Consiglio Nazionale Delle Ricerche
    Inventors: Monica Sturaro, Angelo Viotti, Paolo Falagiani, Giovanni Mistrello, Daniela Roncarolo, Stefania Zanotta
  • Patent number: 6794360
    Abstract: The invention relates to the discovery that various proteins isolated from ticks are effective in the treatment and prevention of allergic rhinitis. These proteins may most suitably be applied to an effected area and are thus effective to treat this condition and to ameliorate its symptoms.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: September 21, 2004
    Assignee: Evolutec Limited
    Inventors: Patricia Anne Nuttall, Guido Christiaan Paesen
  • Patent number: 6787642
    Abstract: The present invention discloses the existence of novel insect transporters that can be used as targets for screening of new insecticides. This invention provides nucleic acids which encode the following insect cell membrane transporters: acetylcholine transporters, serotonin transporters, proline transporters, glutamate transporters, neurotransmitter transporters encoded by the inebriated gene, orphan transporters, GABA transporters, and LAT transporters. The invention also provides the polypeptides, cells expressing the polypeptides, and methods of using the nucleic acids and polypeptides to identify compounds which bind to or modulate the activity of the above-listed insect cell membrane transporters.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: September 7, 2004
    Assignee: The Regents of the University of California
    Inventors: Sarjeet Gill, Linda S. Ross
  • Patent number: 6737399
    Abstract: The present invention relates to the discovery that various proteins isolated from ticks are effective in the treatment of conjunctivitis. These proteins may most suitably be applied topically to an affected area and are effective to ameliorate the symptoms of this condition.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: May 18, 2004
    Assignee: Evolutec Ltd.
    Inventors: Patricia Anne Nuttall, Guido Christiaan Paesen
  • Patent number: 6677443
    Abstract: The present invention is directed to a lepidopteran octopamine/tyramine transporter. Nucleic acids encoding the transporter, and vectors and host cells comprising the nucleic acids are provided. The invention further provides a recombinant octopamine/tyramine transporter, kits and compositions comprising the transporter, and methods of identifying agents that mediate the activity of the transporter.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: January 13, 2004
    Assignee: Her Majesty the Queen in Right of Canada as represented by the Minister the Department of Agriculture and Agrifood Canada
    Inventors: Tabita Malutan, Cameron Donly, Stanley Caveney
  • Patent number: 6653460
    Abstract: A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: November 25, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Robert Newcomb, Andrew L. Palma, Balazs G. Szoke, Katalin Tarczy-Hornoch, William F. Hopkins, Ruth L. Cong, George P. Miljanich, Robin Dean, Laszlo Nadasdi, Laszlo Urge, Stephen Scott Bowersox
  • Patent number: 6555109
    Abstract: A substantially non-toxic fraction isolated from the venom of Vipera xanthina is disclosed which fraction has an analgesic effect. The fraction is preferably purified on an ion exchange column from Vipera xanthina palestinae. Also described are a pharmaceutical composition for use as an analgesic comprising the non-toxic fraction, and a method for the relief of pain comprising administrating the non-toxic fraction.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: April 29, 2003
    Assignee: S.I.S. Shulov Institute for Science Ltd.
    Inventors: Abaron Shulov, Naftali Primor
  • Patent number: 6489140
    Abstract: The present invention relates to flea ecdysone receptor and ultraspiracle proteins; to flea ecdysone receptor and ultraspiracle nucleic acid molecules, including those that encode such flea ecdysone receptor and ultraspiracle proteins; to antibodies raised against such flea ecdysone receptor and ultraspiracle proteins; and to compounds that inhibit flea ecdysone receptor and/or ultraspiracle activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising a protective compound derived from a protein of the present invention that inhibits the binding between ecdysone receptor and ecdysone as well as the use of such therapeutic compositions to protect animals from flea infestation.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: December 3, 2002
    Inventors: Nancy Wisnewski, Anna M. Becher, Eric Jarvis
  • Patent number: 6432407
    Abstract: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: August 13, 2002
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Kazutoh Takesako, Takashi Okado, Tomoko Yagihara, Masanobu Kuroda, Yoshimi Onishi, Ikunoshin Kato, Kazuo Akiyama, Hiroshi Yasueda, Hideyo Yamaguchi
  • Patent number: 6406900
    Abstract: The present invention relates to flea serine protease proteins and flea cysteine protease proteins; to flea serine protease and cysteine protease nucleic acid molecules, including those that encode such proteins; to antibodies raised against such proteins; and to compounds that inhibit flea serine protease and/or cysteine protease activities. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitors. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies, and/or inhibitors as well as the use of such therapeutic compositions to protect a host animal from flea infestation.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: June 18, 2002
    Assignee: Heska Corporation
    Inventors: Shirley Wu Hunter, Gary L. Stiegler, Patrick J. Gaines
  • Patent number: 6358927
    Abstract: Synthetic peptide fragments from pheromone biosynthesis activating neuropeptide PBAN (1-33)-NH2 of Helicoverpa zea which have either pheromone biosynthesis stimulating or inhibiting activity.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: March 19, 2002
    Assignee: State of Israel
    Inventor: Miriam Altstein
  • Patent number: 6316221
    Abstract: A method which enable to provide sufficient amount of insect OBP, and moreover, to produce on a large scale under the condition of physiological activation is proposed. The functional expression of pheromone binding protein from B. mori, whereby it is expressed with Escherichia coli by the pET-22b vector which contains the pe1B signal peptide.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: November 13, 2001
    Assignee: Japan as represented by Director General of National Institute of Sericultural and Entomological Science, Ministry of Agriculture Forestry and Fisheries
    Inventors: Walter Soares Leal, Hubert Wojtasek
  • Patent number: 6265376
    Abstract: Novel plectoxins isolated from the Primitive Hunting Spider, Plectreurys tristis are described, and their amino acid sequences are presented. These are toxic to various groups of insects, including Lepidopterans. A particularly potent plectoxin is Plt-VI. The plectoxins may be cloned into a baculovirus vector and hasten its speed of kill.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: July 24, 2001
    Assignee: Novartis AG
    Inventors: Douglas J. Leisy, Gary B. Quistad, Wayne S. Skinner
  • Patent number: 6251862
    Abstract: Novel polypeptides are isolated from the venom of the parasitic wasp, Bracon hebetor, and are designated Brh-I to Brh-V. These polypeptides are paralytic and/or toxic to insects. The entire amino acid sequence of Brh-I and the DNA encoding it is also determined. These polypeptides may be cloned into a baculovirus, and used for insect control.
    Type: Grant
    Filed: May 31, 1996
    Date of Patent: June 26, 2001
    Assignee: Syngenta Participations AG
    Inventors: Gary B. Quistad, Douglas J. Leisy
  • Patent number: 6235283
    Abstract: This invention relates to an antigen isolated from the cattle tick Boophilus microplus and to the gene coding for that antigen and to the protein product of that gene. The antigen when used in part or in entirety as an immunogen administered to cattle as a vaccine results in the production by the cattle of an immune response which is capable of damaging ticks feeding on vaccinated cattle to such an extent that the survival of such ticks is decreased and/or the reproductive capacity of the ticks is decreased to such an extent that the antigen coded for by the gene can be used as an effective vaccine against said ticks.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 22, 2001
    Assignees: Biotechnology Australia Pty. Ltd., Commonwealth Scienticfic and Industrial Research Organization
    Inventors: Gary Stewart Cobon, Joanna Terry Moore, Law Anthony Yorke Johnston, Peter Willadsen, David Harold Kemp, Alagacone Sriskantha, George Alfred Riding, Keith Norman Rand
  • Patent number: 6162430
    Abstract: A method is provided that accelerates the rate of kill of pests such as from the order Lepidoptera. The method comprises treating the pests or their loci with at least two different insect toxins which are expressed from at least one recombinant microbe. Pairs of toxins that do not compete with each other on the same binding site and that differ in their pharmacology have been found to provide synergistic control. Preferred insecticidal microbes are baculoviruses.
    Type: Grant
    Filed: February 6, 1998
    Date of Patent: December 19, 2000
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Rafael Herrmann, Haim Moskowitz
  • Patent number: 6156726
    Abstract: A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: December 5, 2000
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Robert Newcomb, Andrew L. Palma, Balazs G. Szoke, Katalin Tarczy-Hornoch, William F. Hopkins, Ruth L. Cong, George P. Miljanich, Robin Dean, Laszlo Nadasdi, Laszlo Urge, Stephen Scott Bowersox
  • Patent number: 6106844
    Abstract: The present invention is directed to immunogenic peptides from vespid antigen 5. These immunogenic peptides can be used in immunotherapy for vespid venom allergic individuals. The present invention is thus directed to T cell epitopes of vespid antigen 5 that can anergize T cell responses in sensitive individuals.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: August 22, 2000
    Assignee: The Rockfeller University
    Inventor: Te Piao King
  • Patent number: 6074859
    Abstract: According to the present invention, there can be provided a bioluminescent protein, luciferase excellent in thermostability etc. and with high catalytic efficiency.
    Type: Grant
    Filed: July 8, 1998
    Date of Patent: June 13, 2000
    Assignee: Kikkoman Corporation
    Inventors: Kozo Hirokawa, Naoki Kajiyama, Seiji Murakami
  • Patent number: 6063902
    Abstract: The present invention relates to ectoparasite histamine releasing factor (HRF) proteins; to ectoparasite HRF nucleic acid molecules, including those that encode such HRF proteins; to antibodies raised against such HRF proteins; and to compounds that inhibit ectoparasite HRF activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to reduce ectoparasite burden of animals.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: May 16, 2000
    Assignee: Heska Corporation
    Inventor: Gary L. Stiegler
  • Patent number: 6034217
    Abstract: A gene coding for a peptidoglysan recognition peptide (PGRP) is cloned, a recombinant vector into which said gene is introduced is obtained, and a transformant transformed with said recombinant vector is cultivated, thereby producing the PGRP in large amounts at high purity.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: March 7, 2000
    Assignee: Wako Pure Chemical Industries, Ltd.
    Inventors: Masaaki Ashida, Masanori Ochiai, Masakazu Tsuchiya
  • Patent number: 5958887
    Abstract: The present invention relates to the use of hymenoptera venom or proteinaceous or polypeptide components contained therein in the manufacture of a medicament for treating DNA virus infections, and to a method for treatment of mammalian DNA virus infections which uses hymenoptera venom or proteinaceous or polypeptide components contained therein.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: September 28, 1999
    Inventors: Michael Hansen, Ole Gyring Nieben
  • Patent number: 5955573
    Abstract: Stabilized ubiquitin-lytic peptide fusion polypeptides and a method of making the same by sub-cloning nucleic acid sequences coding for lytic peptides into a plasmid vector comprising a promoter and ubiquitin polypeptide coding sequence, wherein the ubiquitin polypeptide sequence is linked to the 5' end of the lytic peptide nucleic acid sequence and is translated as a fusion polypeptide.
    Type: Grant
    Filed: July 21, 1995
    Date of Patent: September 21, 1999
    Assignee: Demegen, Inc.
    Inventors: Joan Garbarino, Jesse Jaynes, William Belknap
  • Patent number: 5904922
    Abstract: Antivenoms to snake, spider, scorpion and jelly fish venoms are produced for treatment of humans and animals, and for analytical use. Polyvalent antivenoms are produced containing immunoglobulin which is greater than fifty percent venom reactive. Purified polyvalent antivenom is derived from a first polyvalent antivenom having two or more monovalent subpopulations, and purified such that greater than fifty percent of the monovalent subpopulations are recovered by weight. The antivenoms can be horse or avian such as chicken antivenom. Chicken antivenom is obtained using a whole venom that is not glutaraldehyde pretreated, and the antivenom contains yolk immunoglobulin. Antivenoms are purified with an antigen matrix containing a single whole venom or a plurality of whole venoms covalently attached to an insoluble support such as aldehyde-activated agarose. Preferably, the whole venoms forming the plurality of whole venoms are selected from the four whole venoms of C. atrox, B. atrox, C. adamanteus and C.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: May 18, 1999
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventor: Sean B. Carroll
  • Patent number: 5858970
    Abstract: A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: January 12, 1999
    Assignee: Bio-Technology General Corp.
    Inventors: Elisha P. Zeelon, Moshe M. Werber, Avigdor Levanon
  • Patent number: 5827829
    Abstract: The present invention relates to the use of hymenoptera venom or proteinaceous or polypeptide components contained therein in the manufacture of a medicament for treating DNA virus infections, and to a method for the treatment of mammalian DNA virus infections which uses hymenoptera venom or proteinaceous or polypeptide components contained therein.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: October 27, 1998
    Inventors: Michael Hansen, Ole Gyring Nieben